- Home
- BCYC
as 10-07-2025 3:30pm EST
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.
| Founded: | 2009 | Country: | United Kingdom |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 492.1M | IPO Year: | 2019 |
| Target Price: | $22.91 | AVG Volume (30 days): | 303.4K |
| Analyst Decision: | Buy | Number of Analysts: | 11 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.50 | EPS Growth: | N/A |
| 52 Week Low/High: | $6.10 - $28.67 | Next Earning Date: | 10-30-2025 |
| Revenue: | $19,281,000 | Revenue Growth: | -51.28% |
| Revenue Growth (this year): | -18.17% | Revenue Growth (next year): | -0.03% |
Stock Insider Trading Activity of Bicycle Therapeutics plc (BCYC)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Skynner Michael | BCYC | CHIEF TECHNOLOGY OFFICER | Oct 3 '25 | Sell | $8.41 | 978 | $8,224.98 | 118,277 | |
| Hannay Michael Charles Ferguson | BCYC | CHIEF PROD & SUPPLY CHAIN OFF | Oct 3 '25 | Sell | $8.41 | 250 | $2,102.50 | 53,102 | |
| Thompson Travis Alvin | BCYC | CHIEF ACCOUNTING OFFICER | Oct 3 '25 | Sell | $8.41 | 103 | $866.23 | 31,197 | |
| Milnes Alistair | BCYC | CHIEF OPERATING OFFICER | Oct 3 '25 | Sell | $8.41 | 978 | $8,224.98 | 93,377 | |
| Lee Kevin | BCYC | CHIEF EXECUTIVE OFFICER | Oct 3 '25 | Sell | $8.41 | 3,231 | $27,172.71 | 475,310 | |
| Skynner Michael | BCYC | CHIEF TECHNOLOGY OFFICER | Oct 2 '25 | Sell | $8.40 | 824 | $6,921.60 | 118,277 | |
| Hannay Michael Charles Ferguson | BCYC | CHIEF PROD & SUPPLY CHAIN OFF | Oct 2 '25 | Sell | $8.40 | 473 | $3,973.20 | 53,102 | |
| Thompson Travis Alvin | BCYC | CHIEF ACCOUNTING OFFICER | Oct 2 '25 | Sell | $8.40 | 221 | $1,856.40 | 31,197 | |
| Young Alethia | BCYC | Chief Financial Officer | Oct 2 '25 | Sell | $8.50 | 482 | $4,103.13 | 44,704 | |
| Milnes Alistair | BCYC | CHIEF OPERATING OFFICER | Oct 2 '25 | Sell | $8.40 | 1,147 | $9,634.80 | 93,377 |
Latest Bicycle Therapeutics plc News
BCYC Breaking Stock News: Dive into BCYC Ticker-Specific Updates for Smart Investing
MT Newswires
22 days ago
European Equities Traded in the US as American Depositary Receipts Edge Lower in Tuesday Trading
MT Newswires
23 days ago
European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading
MT Newswires
3 months ago
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading; Up 2.5% for Week
MT Newswires
4 months ago
European Equities Traded in the US as American Depositary Receipts Edge Higher Wednesday
Simply Wall St.
4 months ago
Is Bicycle Therapeutics (NASDAQ:BCYC) In A Good Position To Invest In Growth?
Business Wire
4 months ago
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire
5 months ago
Bicycle Therapeutics Announces Poster Presentations at the 2025 ASCO Annual Meeting
GuruFocus.com
5 months ago
Eckert & Ziegler SE (XTER:EUZ) Q1 2025 Earnings Call Highlights: Strategic Partnerships and ...
Compare BCYC vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BCYC Bicycle Therapeutics plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.